Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 10 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| CRISPR Therapeutics AG | 1,730,179 | reported | 16 Jul 2025 | tx 21+5,410,390−3,154,127 |
| Nkarta, Inc. | 46,000 | reported | 05 Jun 2025 | tx 10+3,467,544 |
| Design Therapeutics, Inc. | 19,000 | reported | 10 Jun 2025 | tx 13+6,609,476−8,763,656 |
| Turning Point Therapeutics, Inc. | 0 | reported | 17 Aug 2022 | tx 14+2,285,660−8,705,728 |
| Principia Biopharma Inc. | 0 | reported | 28 Sept 2020 | tx 20+3,023,810−5,408,146 |
| GENOCEA BIOSCIENCES, INC. | 0 | reported | 10 Feb 2014 | tx 7+1,671,667−18,181,958 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 16 Jul 2025 | PURCHASE | CRISPR Therapeutics AG | 22,319 | 52.03 USD | |
| 16 Jul 2025 | PURCHASE | CRISPR Therapeutics AG | 960,983 | 52.03 USD | first after silence |
| 16 Jul 2025 | PURCHASE | CRISPR Therapeutics AG | 6,510 | 52.03 USD | |
| 10 Jun 2025 | GRANT_AWARD | Design Therapeutics, Inc. | 19,000 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | Nkarta, Inc. | 46,000 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | CRISPR Therapeutics AG | 13,000 | 0.00 USD | deriv |
| 13 Jun 2024 | GRANT_AWARD | Design Therapeutics, Inc. | 19,000 | 0.00 USD | deriv |
| 13 Jun 2024 | GRANT_AWARD | Nkarta, Inc. | 22,500 | 0.00 USD | deriv |
| 30 May 2024 | GRANT_AWARD | CRISPR Therapeutics AG | 13,000 | 0.00 USD | deriv |
| 27 Mar 2024 | PURCHASE | Nkarta, Inc. | 1,548,341 | 10.00 USD | |
| 27 Mar 2024 | PURCHASE | Nkarta, Inc. | 451,659 | 10.00 USD | first after silence |
| 27 Feb 2024 | GRANT_AWARD | CRISPR Therapeutics AG | 216,578 | 71.50 USD | |
| 27 Feb 2024 | GRANT_AWARD | CRISPR Therapeutics AG | 769,196 | 71.50 USD | |
| 27 Feb 2024 | GRANT_AWARD | CRISPR Therapeutics AG | 63,177 | 71.50 USD | |
| 08 Jun 2023 | GRANT_AWARD | CRISPR Therapeutics AG | 13,000 | 0.00 USD | deriv |
| 07 Jun 2023 | GRANT_AWARD | Nkarta, Inc. | 22,500 | 0.00 USD | deriv |
| 31 May 2023 | GRANT_AWARD | Design Therapeutics, Inc. | 15,000 | 0.00 USD | deriv |
| 19 Dec 2022 | PURCHASE | Design Therapeutics, Inc. | 360,000 | 8.63 USD | |
| 20 Dec 2022 | PURCHASE | Design Therapeutics, Inc. | 40,000 | 8.14 USD | |
| 16 Dec 2022 | PURCHASE | Design Therapeutics, Inc. | 500,000 | 8.28 USD | |
| 17 Aug 2022 | OTHER | Turning Point Therapeutics, Inc. | 2,253,660 | 76.00 USD | |
| 17 Aug 2022 | OTHER | Turning Point Therapeutics, Inc. | 15,000 | — | deriv |
| 17 Aug 2022 | OTHER | Turning Point Therapeutics, Inc. | 8,500 | — | deriv |
| 17 Aug 2022 | OTHER | Turning Point Therapeutics, Inc. | 8,500 | — | deriv |
| 15 Jun 2022 | GRANT_AWARD | Design Therapeutics, Inc. | 15,000 | 0.00 USD | deriv |
5 purchases reported after at least 12 months of silence — most recent on 16 Jul 2025.